Prolonged glucosuria and relapse of diabetic ketoacidosis related to SGLT2-inhibitor therapy

Gregory P Westcott; Alissa R Segal; Joanna Mitri; Florence M Brown

doi:10.1002/edm2.117

Prolonged glucosuria and relapse of diabetic ketoacidosis related to SGLT2-inhibitor therapy

Endocrinol Diabetes Metab. 2020 Feb 29;3(2):e00117. doi: 10.1002/edm2.117. eCollection 2020 Apr.

Authors

Gregory P Westcott^{1

2}, Alissa R Segal^{1

3}, Joanna Mitri¹, Florence M Brown¹

Affiliations

¹ Joslin Diabetes Center Boston Massachusetts.
² Beth Israel Deaconess Medical Center Boston Massachusetts.
³ MCPHS University Boston Massachusetts.

Abstract

SGLT2 inhibitors (SGLT2i) are glucose-lowering medications which increase the renal threshold for glucose reabsorption and promote glucosuria. Treatment with these agents raises serum ketone levels, and cases of diabetic ketoacidosis (DKA) during therapy have been reported. The duration of glucosuria and inpatient course of SGLT2i-related DKA, however, is not well-characterized. We report 11 inpatient cases of SGLT2i-related DKA, including a subset of patients who experienced prolonged glucosuria and relapse of DKA during their hospitalization.

Keywords: SGLT2 inhibitors; diabetic ketoacidosis; inpatient diabetes management; prolonged glucosuria.

Publication types

Case Reports